Dissuasive cigarettes as a tobacco control measure: a scoping review.

OBJECTIVE: The aim was to identify and review the research literature on dissuasive cigarettes, including key concepts, types, sources of evidence and research gaps. DATA SOURCES: PubMed, Scopus and Web of Science databases were searched up to January 2023 with no language or date restrictions. All study designs were included. Reference lists of the identified studies were manually searched. Studies on tobacco products other than cigarettes or on external cigarette packaging alone were excluded. STUDY SELECTION: Two reviewers screened titles and abstracts independently using eligibility criteria. The full text of the selected articles was subsequently screened independently by two reviewers to confirm eligibility. DATA EXTRACTION: Two reviewers independently extracted data from all studies using data abstraction forms. Results were reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist. DATA SYNTHESIS: We identified 24 original studies, 3 review articles and 4 commentary articles. Research on dissuasive cigarettes was reported from Australia, New Zealand, Europe and North America. We presented results in four themes: the concept of dissuasive cigarettes; approaches and types; potential benefits, barriers and concerns; and current research gaps. CONCLUSIONS: Dissuasive cigarettes represent a promising strategy that could be used in tobacco control. Parallel implementation with plain packaging would be feasible and synergistic.

Histological, haematological, and thyroid hormones toxicity of female rats orally exposed to CuO/ZnO core/shell nanoparticles synthesized by Ar plasma jets.

Advancements in nanomedicine helped scientists design a new class of nanoparticles known as hybrid nanoparticles (core/shell) for diagnostic and therapeutic purposes. An essential requirement for the successful use of nanoparticles in biomedical applications is their low toxicity. Therefore, toxicological profiling is necessary to understand the mechanism of nanoparticles. The current study aimed to assess the toxicological potential of CuO/ZnO core/shell nanoparticles with a size of 32 nm in Albino female rats. In vivo toxicity was evaluated by oral administration of 0, 5, 10, 20, and 40 (mg/L) of CuO/ZnO core/shell nanoparticles to a female rate for 30 consecutive days. During the time of treatment, no deaths were observed. The toxicological evaluation revealed significant (p < 0.01) alteration in white blood cells (WBC) at a 5 (mg/L) dose. Also, increase in red blood cells (RBC) at 5, 10 (mg/L) doses, while hemoglobin (Hb) levels and hematocrit (HCT) increased at all doses. This maybe indicates that the CuO/ZnO core/shell nanoparticles stimulated the rate of blood corpuscle generation. The anaemia diagnostic indices (mean corpuscular volume MCV and mean corpuscular haemoglobin MCH) remained unchanged throughout the experiment for all the doses tested 5, 10, 20, and 40 (mg/L). According to the results of this study, exposure to CuO/ZnO core/shell NPs deteriorates the Triiodothyronine hormone (T3) and a Thyroxine hormone (T4) activated by Thyroid-Stimulating Hormone (TSH), which is generated and secreted from the pituitary gland. There is possibly related to an increase in free radicals and a decrease in antioxidant activity. Significant (p < 0.01) growth retardation in all groups treated due to rats' infection by Hyperthyroidism induced by thyroxine (T4) level increase. Hyperthyroidism is a catabolic state related to increased energy consumption, protein turnover, and lipolysis. Usually, these metabolic effects result in weight reduction and a decrease in fat storage and lean body mass. The histological examination indicates that the low concentrations of CuO/ZnO core/shell nanoparticles are safe for desired biomedical applications.

Two patients with Canavan disease and structural modeling of a novel mutation.

Canavan disease (CD) is a rare fatal childhood neurological autosomal recessive genetic disease caused by mutations in the ASPA gene, which lead to catalytic deficiency of the ASPA enzyme, which catalyzes the hydrolysis of N-acetyl-L-aspartate (NAA) into aspartate and acetate. CD occurs frequently among Ashkenazi Jewish population, however it has been reported in many other ethnic groups with significantly lower frequency. Here, we report on two Egyptian patients diagnosed with CD, the first patient harbors five missense mutations (c.427 A > G; p. I143V, c.502C > T; p. R168C, c.530 T > C; p. I177T, c.557 T > C; p. V186D c.548C > T; p. P183L) and a silent mutation (c.693 C > T; p. Y231Y). The second patient was found to be homozygous for two missense mutations (c.427 A > G; p. I143V and c.557 T > A; p. V186D). Furthermore, molecular modeling of the novel mutation p. P183L provides an instructive explanation of the mutational impact on the protein structure that can affect the function of the ASPA. Here, the clinical, radiological, and biochemical profile of the two patients are reviewed in details.

Estimation of in vivo toxicity of MgO/ZnO core/shell nanoparticles synthesized by eco-friendly non-thermal plasma technology.

MgO/ZnO core/shell nanoparticles were synthesized using the atmosphere plasma jets technique. The physical properties of the synthesized nanoparticles were investigated by a series of techniques, including X-ray diffraction (XRD), X-ray dispersive spectroscopy (EDS), and transmission electron microscopy (TEM). XRD and EDS analyses confirmed the purity of the nanoparticles synthesized with an average nanoparticle crystallite size of 36 nm. TEM confirmed the successful synthesis of spindle-shaped MgO/ZnO core/shell nanoparticles with an average size of 70 nm. To evaluate their toxicity, the MgO/ZnO core/shell nanoparticles were tested in vivo. Twenty-five albino female rats were randomly divided into five groups (five rats in each group); one was used as the control group and the other four as the experimental groups. Doses of the MgO/ZnO core/shell nanoparticles solution were orally administered to the test groups to examine the toxicity. For 30 consecutive days, each rat in test groups 2-5 received 1 mL of the MgO/ZnO core/shell nanoparticles solution at the respective doses of 1.25, 2.5, 5, and 10 mg L-1. The rats' growth, hematology, thyroid gland function, and histopathology were examined after 30 days. Findings indicate that the growth retardation in the rats treated with MgO/ZnO core/shell nanoparticles may be due to their infection by Hyperthyroidism. The hematology results show the nonsignificant effect of MgO/ZnO core/shell nanoparticles on white blood cells, implying that these nanoparticles have no harmful impact on the immune system. Moreover, the levels of the thyroxine and thyroid-stimulating hormones increased, and that of the triiodothyronine hormone decreased. The histological analysis results show that low concentrations of MgO/ZnO core/shell nanoparticles are safe for desired biomedical applications.

Untreated submandibular megalith for over 60 years.

Intra-parenchymal sialolithiasis and subsequent fibrosis of the submandibular salivary glands is a rare disorder. The resulting swelling, pain, and infection derives affected patients to seek treatment. We present the case of an 85-years-old Saudi male patient who suffered from repeated swelling and infection in the left submandibular region which was misdiagnosed and treated for over 60 years as dental infection, infected skin sebaceous gland or lipoma. The presented case represents the largest intra-glandular submandibular stone with the longest duration ever reported in the medical literature.

Large eruption complex odontome in a Saudi patient.

Odontomas are odontogenic tumors formed of various dental tissues. They are classified into: central odontomas that are common, eruption odontomas that are rare with only 23 cases reported to date, and peripheral odontomas that are also rare. We present a case of a large complex eruption odontome in a 24-year-old Saudi male. 

Burden of visceral leishmaniasis in villages of eastern Gedaref State, Sudan: an exhaustive cross-sectional survey.

BACKGROUND: Since December 2009, Médecins Sans Frontières has diagnosed and treated patients with visceral leishmaniasis (VL) in Tabarak Allah Hospital, eastern Gedaref State, one of the main endemic foci of VL in Sudan. A survey was conducted to estimate the VL incidence in villages around Tabarak Allah. METHODS: Between the 5(th) of May and the 17(th) of June 2011, we conducted an exhaustive door-to-door survey in 45 villages of Al-Gureisha locality. Deaths were investigated by verbal autopsies. All individuals with (i) fever of at least two weeks, (ii) VL diagnosed and treated in the previous year, and (iii) clinical suspicion of post-kala-azar dermal leishmaniasis (PKDL) were referred to medical teams for case ascertainment. A new case of VL was a clinical suspect with a positive rk39 rapid test or direct agglutination test (DAT). RESULTS: In the 45 villages screened, 17,702 households were interviewed, for a population of 94,369 inhabitants. The crude mortality rate over the mean recall period of 409 days was 0.13/10'000 people per day. VL was a possible or probable cause for 19% of all deaths. The VL-specific mortality rate was estimated at 0.9/1000 per year. The medical teams examined 551 individuals referred for a history of fever of at least two weeks. Out of these, 16 were diagnosed with primary VL. The overall incidence of VL over the past year was 7.0/1000 persons per year, or 7.9/1000 per year when deaths possibly or probably due to VL were included. Overall, 12.5% (11,943/95,609) of the population reported a past VL treatment episode. DISCUSSION AND CONCLUSION: VL represents a significant health burden in eastern Gedaref State. Active VL case detection had a very low yield in this specific setting with adequate access to care and may not be the priority intervention to enhance control in similar contexts.